Medeon Biodesign, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 06, 2022 at 02:59 am IST
Share
Medeon Biodesign, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 29.35 million compared to TWD 38.39 million a year ago. Net loss was TWD 191.74 million compared to net income of TWD 2,436.48 million a year ago. Basic loss per share from continuing operations was TWD 2.63 compared to TWD 1.78 a year ago. Diluted loss per share from continuing operations was TWD 2.63 compared to TWD 1.78 a year ago. Basic loss per share was TWD 2.63 compared to basic earnings per share of TWD 33.48 a year ago. Diluted loss per share was TWD 2.63 compared to diluted earnings per share of TWD 33.48 a year ago.
For the six months, sales was TWD 219.89 million compared to TWD 49.26 million a year ago. Net loss was TWD 124.57 million compared to net income of TWD 2,363.89 million a year ago. Basic loss per share from continuing operations was TWD 1.71 compared to TWD 3.08 a year ago. Diluted loss per share from continuing operations was TWD 1.71 compared to TWD 3.08 a year ago. Basic loss per share was TWD 1.71 compared to basic earnings per share of TWD 32.48 a year ago. Diluted loss per share was TWD 1.71 compared to diluted earnings per share of TWD 32.48 a year ago.
Medeon Biodesign, Inc. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of medical equipment. The Company's main products include medical apparatus and instruments used in laparoscopic minimally invasive surgeries and cardiac catheter-related minimally invasive surgeries. The Company distributes its products in domestic market and to overseas markets.